| |
Approaching early development strategically is critical to the later success of a drug candidate. Discover the current challenges and considerations for biotechs to maximize drug development outcomes. +(2)+(2).png)
|
|
Today’s Big NewsJan 15, 2025 |
|
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about packaging innovations and aseptic filling solutions that meet the demands of emerging therapies and ensure product integrity, safety and efficiency. 
|
|
| By Angus Liu,Zoey Becker,Kevin Dunleavy,Fraiser Kansteiner,Eric Sagonowsky Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more companies are set to take the stage on Wednesday. |
|
|
|
By Gabrielle Masson Following GSK’s deal-heavy end to 2024, Chief Scientific Officer Tony Wood, Ph.D., doesn’t expect the trend to let up in the new year, zeroing in on partnerships that can expand knowledge about genetic factors driving disease. And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways to build past the GLP-1 space. |
By Conor Hale The project will launch a Care Innovation Hub within UCSF’s Department of Radiology & Biomedical Imaging, to serve as a home that brings together the university’s oncology and brain research and GE HealthCare’s product development efforts. |
By Fraiser Kansteiner,Kevin Dunleavy Like many other biopharma companies presenting at this year’s J.P. Morgan Healthcare Conference, Eli Lilly took a chance on Tuesday to share its preliminary sales results for 2024. Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over well with investors. |
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now. 
|
|
By Kevin Dunleavy In response to the anti-vaccine movement in the U.S., CEOs from GSK and Sanofi stressed the need for transparency in discussing the value of vaccines. |
By Nick Paul Taylor Neumora Therapeutics’ phase 3 fail was worse than analysts feared. The biotech provided a closer look at the data Tuesday, shutting down one source of hope that analysts had clung to after the initial blow. |
By James Waldron A month after halting dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial hypertension drug, Keros Therapeutics has now pulled the plug on the study entirely. |
By Conor Hale According to Philips and the FDA, some cardiac events recorded by electrocardiogram were not correctly flagged and routed to clinicians for full review. |
By James Waldron OS Therapies’ HER2-focused immunotherapy prevented patients’ lung cancer from returning in 33% of cases, hitting the primary goal of a phase 2 trial. |
By Kevin Dunleavy One day after Samsung Biologics revealed in a regulatory filing that it had signed its largest contract in company history, the CDMO giant said it's considering the construction of a sixth manufacturing plant. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we dive into 2024's batch of new FDA drug approvals, highlighting some potential blockbusters and shifts from previous years' lists. |
|
|---|
|
|
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
.+(1).png)
